Search results
Results from the WOW.Com Content Network
90 Y plays a significant role in the treatment of hepatocellular carcinoma (HCC), leukemia, and lymphoma, although it has the potential to treat a range of tumors. [9] Trans-arterial radioembolization is a procedure performed by interventional radiologists, in which 90 Ymicrospheres are injected into the arteries supplying the tumor. [10]
Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation oncology; however, when irradiating using external beam radiotherapy, the beam will always need to travel through healthy tissue, and the normal liver tissue is very ...
Low-risk patients with unresectable liver cancer appear to gain control over their malignancies for at least 2 years when treated with TheraSphere. They survived a median of 800 days compared with a median of 258 days for high risk patients (P <.0001) in a study of 140 patients (106 male). The patients underwent 238 administrations of the ...
During active cancer treatment, patients face many smaller ... that 26 million people will be diagnosed by 2030 — Saini said chemo mouth is likely to be one of the most common side effects. ...
Yttrium (90 Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. [1]The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, [2] a radioisotope which destroys the tumour cells.
Kate Middleton is opening up about the long-term side effects of her cancer treatment.. On Tuesday, Jan. 14, the Princess of Wales spoke with staff during a surprise visit to the Royal Marsden ...
Various approaches to approve effectiveness and limit side effects are being investigated, including radiosensitising drugs, fractionation regimes and new radionuclides. [16] Alpha emitters, which have much shorter ranges in tissue (limiting the effect on nearby healthy tissue), such as bismuth-213 or actinium-225 labelled DOTATOC are of ...
The ligand is the target binding site, it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. The different types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, I-125, etc.